JP2012531442A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012531442A5 JP2012531442A5 JP2012517802A JP2012517802A JP2012531442A5 JP 2012531442 A5 JP2012531442 A5 JP 2012531442A5 JP 2012517802 A JP2012517802 A JP 2012517802A JP 2012517802 A JP2012517802 A JP 2012517802A JP 2012531442 A5 JP2012531442 A5 JP 2012531442A5
- Authority
- JP
- Japan
- Prior art keywords
- liquid composition
- composition according
- botulinum toxin
- group
- range
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 55
- 239000007788 liquid Substances 0.000 claims 53
- 108030001720 Bontoxilysin Proteins 0.000 claims 26
- 229940053031 botulinum toxin Drugs 0.000 claims 23
- 239000008247 solid mixture Substances 0.000 claims 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical class CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 15
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 15
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 15
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims 13
- 239000002736 nonionic surfactant Substances 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 9
- 150000002840 non-reducing disaccharides Chemical class 0.000 claims 9
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 8
- 239000000945 filler Substances 0.000 claims 8
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical class OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 8
- 238000000034 method Methods 0.000 claims 8
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 8
- 239000000872 buffer Substances 0.000 claims 7
- 150000001413 amino acids Chemical group 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims 5
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 5
- 229930006000 Sucrose Natural products 0.000 claims 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 5
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 5
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical class O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims 5
- 238000001035 drying Methods 0.000 claims 5
- 239000011976 maleic acid Substances 0.000 claims 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims 5
- 239000005720 sucrose Substances 0.000 claims 5
- 239000011975 tartaric acid Substances 0.000 claims 5
- 235000002906 tartaric acid Nutrition 0.000 claims 5
- 150000004043 trisaccharides Chemical class 0.000 claims 5
- 108010088751 Albumins Proteins 0.000 claims 4
- 102000009027 Albumins Human genes 0.000 claims 4
- 230000015572 biosynthetic process Effects 0.000 claims 4
- 239000013078 crystal Substances 0.000 claims 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 3
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 claims 3
- 229920001213 Polysorbate 20 Polymers 0.000 claims 3
- 229920001219 Polysorbate 40 Polymers 0.000 claims 3
- 229920001214 Polysorbate 60 Polymers 0.000 claims 3
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims 3
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 claims 3
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 claims 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 3
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims 3
- IJCWFDPJFXGQBN-RYNSOKOISA-N [(2R)-2-[(2R,3R,4S)-4-hydroxy-3-octadecanoyloxyoxolan-2-yl]-2-octadecanoyloxyethyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCCCCCCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCCCCCCCCCCCC IJCWFDPJFXGQBN-RYNSOKOISA-N 0.000 claims 3
- LWZFANDGMFTDAV-BURFUSLBSA-N [(2r)-2-[(2r,3r,4s)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] dodecanoate Chemical compound CCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O LWZFANDGMFTDAV-BURFUSLBSA-N 0.000 claims 3
- 238000004108 freeze drying Methods 0.000 claims 3
- 239000003349 gelling agent Substances 0.000 claims 3
- 239000008363 phosphate buffer Substances 0.000 claims 3
- 229920001983 poloxamer Polymers 0.000 claims 3
- 229960000502 poloxamer Drugs 0.000 claims 3
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 claims 3
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims 3
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 claims 3
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims 3
- 239000000249 polyoxyethylene sorbitan monopalmitate Substances 0.000 claims 3
- 235000010483 polyoxyethylene sorbitan monopalmitate Nutrition 0.000 claims 3
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 claims 3
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 claims 3
- 229940068977 polysorbate 20 Drugs 0.000 claims 3
- 229940101027 polysorbate 40 Drugs 0.000 claims 3
- 229940113124 polysorbate 60 Drugs 0.000 claims 3
- 229920000053 polysorbate 80 Polymers 0.000 claims 3
- 229940068968 polysorbate 80 Drugs 0.000 claims 3
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims 3
- 235000011067 sorbitan monolaureate Nutrition 0.000 claims 3
- 235000011078 sorbitan tristearate Nutrition 0.000 claims 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims 3
- 229940095064 tartrate Drugs 0.000 claims 3
- 229940074410 trehalose Drugs 0.000 claims 3
- 125000000647 trehalose group Chemical group 0.000 claims 3
- DPVHGFAJLZWDOC-PVXXTIHASA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-3,4,5-triol;dihydrate Chemical compound O.O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DPVHGFAJLZWDOC-PVXXTIHASA-N 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 239000013504 Triton X-100 Substances 0.000 claims 2
- 229920004890 Triton X-100 Polymers 0.000 claims 2
- 239000006172 buffering agent Substances 0.000 claims 2
- 229940126600 bulk drug product Drugs 0.000 claims 2
- 229920000136 polysorbate Polymers 0.000 claims 2
- 229950008882 polysorbate Drugs 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- -1 sorbitan ester Chemical class 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 229940074409 trehalose dihydrate Drugs 0.000 claims 2
- 238000001291 vacuum drying Methods 0.000 claims 2
- 239000004034 viscosity adjusting agent Substances 0.000 claims 2
- 239000004475 Arginine Substances 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 239000004952 Polyamide Substances 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 229920002125 Sokalan® Polymers 0.000 claims 1
- 229920001938 Vegetable gum Polymers 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 239000004584 polyacrylic acid Substances 0.000 claims 1
- 229920002647 polyamide Polymers 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 230000006641 stabilisation Effects 0.000 claims 1
- 238000011105 stabilization Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22043309P | 2009-06-25 | 2009-06-25 | |
| US61/220,433 | 2009-06-25 | ||
| PCT/US2010/040104 WO2010151840A2 (en) | 2009-06-25 | 2010-06-25 | Albumin-free botulinum toxin formulations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012531442A JP2012531442A (ja) | 2012-12-10 |
| JP2012531442A5 true JP2012531442A5 (cg-RX-API-DMAC7.html) | 2013-08-08 |
| JP6043627B2 JP6043627B2 (ja) | 2016-12-14 |
Family
ID=43381023
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012517802A Expired - Fee Related JP6043627B2 (ja) | 2009-06-25 | 2010-06-25 | アルブミン非含有ボツリヌス毒素製剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (6) | US20120107361A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2445521A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6043627B2 (cg-RX-API-DMAC7.html) |
| KR (5) | KR102328155B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN102869373B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2010265888A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI1015938A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2766521C (cg-RX-API-DMAC7.html) |
| CO (1) | CO6491076A2 (cg-RX-API-DMAC7.html) |
| IL (2) | IL268980B (cg-RX-API-DMAC7.html) |
| MX (3) | MX366344B (cg-RX-API-DMAC7.html) |
| SG (1) | SG177357A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2010151840A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
| AU2005251676B2 (en) | 2004-03-03 | 2011-09-29 | Revance Therapeutics, Inc. | Compositions and methods for topical diagnostic and therapeutic transport |
| CN102139099A (zh) * | 2004-07-26 | 2011-08-03 | 莫茨药物股份两合公司 | 包含肉毒杆菌神经毒素的治疗组合物 |
| US9180081B2 (en) * | 2005-03-03 | 2015-11-10 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
| US8168206B1 (en) * | 2005-10-06 | 2012-05-01 | Allergan, Inc. | Animal protein-free pharmaceutical compositions |
| KR102179926B1 (ko) | 2008-12-31 | 2020-11-17 | 레반스 테라퓨틱스, 아이엔씨. | 주사용 보툴리눔 독소 제제 |
| MX366344B (es) * | 2009-06-25 | 2019-07-05 | Revance Therapeutics Inc | Formulaciones de toxina botulinica libres de albumina. |
| LT2490986T (lt) * | 2009-10-21 | 2018-11-26 | Revance Therapeutics, Inc. | Nekompleksinio botulino neurotoksino gryninimo būdai ir sistemos |
| DK2661276T3 (en) * | 2011-01-07 | 2017-10-02 | Revance Therapeutics Inc | TOPICAL COMPOSITION INCLUDING BOTULINUM TOXIN AND A COLOR |
| CA2867511A1 (en) * | 2012-03-22 | 2013-09-26 | Revance Therapeutics, Inc. | Method of treatment of wrinkles using topical chemodenervating agents |
| US20140242110A1 (en) * | 2013-02-28 | 2014-08-28 | Dt Scimed, Llc | Dose, localization, and formulation of botulinum toxins in skin and muscle |
| MX369534B (es) * | 2013-09-08 | 2019-11-11 | Pfizer | Composiciones de neisseria meningitidis y sus metodos. |
| US9480731B2 (en) | 2013-12-12 | 2016-11-01 | Medy-Tox, Inc. | Long lasting effect of new botulinum toxin formulations |
| JP6738739B2 (ja) * | 2014-04-30 | 2020-08-12 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | 膀胱内滴下注入用生物製剤 |
| MX380066B (es) * | 2014-12-23 | 2025-03-11 | Merz Pharma Gmbh & Co Kgaa | Recipiente precargado con toxina botulinica. |
| CN107206175B (zh) | 2015-02-03 | 2021-06-01 | 莫茨制药有限及两合公司 | 肉毒杆菌毒素预填充式容器 |
| SG10202004337WA (en) * | 2015-10-29 | 2020-06-29 | Revance Therapeutics Inc | Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect |
| WO2018038585A1 (ko) * | 2016-08-26 | 2018-03-01 | 주식회사 에이비바이오 | 보툴리눔 독소 및 안정화제를 포함하는 액상 제형 및 이의 제조방법 |
| WO2018038301A1 (en) | 2016-08-26 | 2018-03-01 | Hugel Inc. | Stabilized liquid formulation of botulinum toxin and preparation method thereof |
| PL3432916T3 (pl) * | 2016-09-13 | 2020-04-30 | Allergan, Inc. | Niebiałkowo stabilzowane kompozycje toksyny clostridium |
| CA3044219A1 (en) * | 2016-11-21 | 2018-05-24 | Eirion Therapeutics, Inc. | Transdermal delivery of large agents |
| KR101744900B1 (ko) * | 2017-01-20 | 2017-06-08 | 주식회사 대웅 | 보툴리눔 독소를 포함하는 안정한 액상 조성물 |
| EP3624819A4 (en) * | 2017-05-18 | 2021-03-24 | Revance Therapeutics, Inc. | Methods of treatment for cervical dystonia |
| WO2018236873A1 (en) | 2017-06-19 | 2018-12-27 | President And Fellows Of Harvard College | Methods and compositions for treating a microbial infection |
| WO2019005773A1 (en) * | 2017-06-26 | 2019-01-03 | Bonti, Inc. | CLOSTRIDIAL NEUROTOXIN FORMULATIONS AND USE |
| WO2019046311A1 (en) | 2017-08-28 | 2019-03-07 | Revance Therapeutics, Inc. | TRANSMUCOSAL COMPOSITIONS OF BOTULINUM TOXIN, KITS AND METHODS FOR TREATING BLADDER DISORDERS |
| CA3084175A1 (en) * | 2017-12-04 | 2019-06-13 | Revance Therapeutics, Inc. | Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration |
| KR102063475B1 (ko) * | 2018-02-22 | 2020-01-09 | 주식회사 에이비바이오 | 보툴리눔 독소, 안정화제, 및 국소마취제를 포함하는 액상 제형 및 이의 제조방법 |
| KR102324855B1 (ko) * | 2020-05-20 | 2021-11-11 | 오스템임플란트 주식회사 | 보툴리눔 독소를 포함하는 약제학적 액상 조성물 |
| KR102414997B1 (ko) * | 2020-09-29 | 2022-06-29 | 주식회사 엘지생활건강 | 안정성이 개선된 재조합 보툴리눔 독소 경쇄 단백질 조성물 |
| WO2022075785A1 (ko) * | 2020-10-07 | 2022-04-14 | 주식회사 프로톡스 | 보툴리눔 독소의 진공 건조 방법 |
| WO2022131860A1 (ko) * | 2020-12-18 | 2022-06-23 | 주식회사 에이티지씨 | 보툴리눔 독소의 액상 제제를 장기 보관하기 위한 약제학적 조성물 |
| KR102427362B1 (ko) * | 2021-11-11 | 2022-08-01 | (주)이니바이오 | 보툴리눔 독소 제제의 건조 공정 |
| WO2025059665A1 (en) | 2023-09-15 | 2025-03-20 | Revance Therapeutics, Inc. | Serial treatment with botulinum toxin for cervical dystonia |
| WO2025064729A1 (en) | 2023-09-19 | 2025-03-27 | Revance Therapeutics, Inc. | Treatment with botulinum toxin in patients in need of a rapid onset cosmetic effect and smoother skin appearance |
| GB202318884D0 (en) * | 2023-12-11 | 2024-01-24 | Ipsen Biopharm Ltd | Formulation |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
| NZ256921A (en) | 1992-10-02 | 1996-05-28 | Pharmacia Ab | Formulations of coagulation factor viii and a non-ionic surfactant and their preparation |
| EP1005867B2 (en) | 1993-12-28 | 2010-02-17 | Allergan, Inc. | Botulinum toxins for modulating cholinergic controlled secretions |
| US5512547A (en) | 1994-10-13 | 1996-04-30 | Wisconsin Alumni Research Foundation | Pharmaceutical composition of botulinum neurotoxin and method of preparation |
| US5756468A (en) | 1994-10-13 | 1998-05-26 | Wisconsin Alumni Research Foundation | Pharmaceutical compositions of botulinum toxin or botulinum neurotoxin and methods of preparation |
| GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| US20030095927A1 (en) | 1997-10-01 | 2003-05-22 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders |
| CA2319113A1 (en) | 1998-01-26 | 1999-07-29 | University Of Massachusetts | Biologically active hemagglutinin from type a clostridium botulinum and methods of use |
| TW574036B (en) | 1998-09-11 | 2004-02-01 | Elan Pharm Inc | Stable liquid compositions of botulinum toxin |
| US6358917B1 (en) * | 1999-08-24 | 2002-03-19 | Jean D. A. Carruthers | Cosmetic use of botulinum toxin for treatment of downturned mouth |
| US6544548B1 (en) | 1999-09-13 | 2003-04-08 | Keraplast Technologies, Ltd. | Keratin-based powders and hydrogel for pharmaceutical applications |
| US6844324B1 (en) | 1999-11-12 | 2005-01-18 | Massachusetts Institute Of Technology | Modular peptide mediated intracellular delivery system and uses therefore |
| IL149778A0 (en) | 1999-11-22 | 2002-11-10 | Universal Preservation Technologies Inc | Preservation of sensitive biological material |
| CA2400318C (en) | 2000-02-08 | 2005-06-14 | Allergan, Inc. | Botulinum toxin pharmaceutical compositions |
| US20030118598A1 (en) * | 2000-02-08 | 2003-06-26 | Allergan, Inc. | Clostridial toxin pharmaceutical compositions |
| US7780967B2 (en) * | 2000-02-08 | 2010-08-24 | Allergan, Inc. | Reduced toxicity Clostridial toxin pharmaceutical compositions |
| US6670322B2 (en) | 2000-06-01 | 2003-12-30 | Wisconsin Alumni Research Foundation | Method of targeting pharmaceuticals to motor neurons |
| US6306423B1 (en) | 2000-06-02 | 2001-10-23 | Allergan Sales, Inc. | Neurotoxin implant |
| US20040033241A1 (en) | 2000-06-02 | 2004-02-19 | Allergan, Inc. | Controlled release botulinum toxin system |
| EP1301213B1 (en) * | 2000-07-21 | 2017-01-18 | ReVance Therapeutics, Inc. | Multi-component biological transport systems |
| US20040220100A1 (en) * | 2000-07-21 | 2004-11-04 | Essentia Biosystems, Inc. | Multi-component biological transport systems |
| US7255865B2 (en) * | 2000-12-05 | 2007-08-14 | Allergan, Inc. | Methods of administering botulinum toxin |
| US6787517B1 (en) * | 2000-12-29 | 2004-09-07 | Allergan, Inc. | Agent and methods for treating pain |
| AU2002320127A1 (en) | 2001-06-21 | 2003-01-08 | Surromed, Inc. | Covalent coupling of botulinum toxin with polyethylene glycol |
| EP3192528A1 (en) | 2002-02-14 | 2017-07-19 | Chugai Seiyaku Kabushiki Kaisha | Formulation of anti-il6r antibody-containing solutions comprising a sugar as a stabilizer |
| US20030224020A1 (en) | 2002-05-31 | 2003-12-04 | Zabudkin Alexander F. | Pharmaceutical preparation of botulinum neurotoxin, methods of synthesis and methods of clinical use |
| US20040009180A1 (en) | 2002-07-11 | 2004-01-15 | Allergan, Inc. | Transdermal botulinum toxin compositions |
| US9265725B2 (en) * | 2002-10-25 | 2016-02-23 | Foamix Pharmaceuticals Ltd. | Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof |
| US8119109B2 (en) * | 2002-10-25 | 2012-02-21 | Foamix Ltd. | Foamable compositions, kits and methods for hyperhidrosis |
| RU2206337C1 (ru) | 2002-10-29 | 2003-06-20 | Общество с ограниченной ответственностью "Токсины и сопутствующие продукты" | Лекарственный препарат для лечения мышечных дистоний и способ его получения |
| US20040086532A1 (en) | 2002-11-05 | 2004-05-06 | Allergan, Inc., | Botulinum toxin formulations for oral administration |
| DE10333317A1 (de) | 2003-07-22 | 2005-02-17 | Biotecon Therapeutics Gmbh | Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA) |
| US20100266638A1 (en) * | 2004-02-26 | 2010-10-21 | Allergan, Inc. | Headache treatment method |
| AU2005251676B2 (en) * | 2004-03-03 | 2011-09-29 | Revance Therapeutics, Inc. | Compositions and methods for topical diagnostic and therapeutic transport |
| EP2656859B1 (en) * | 2004-03-03 | 2015-10-21 | ReVance Therapeutics, Inc. | Topical application and transdermal delivery of botulinum toxins |
| US9211248B2 (en) * | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
| GB2416122A (en) * | 2004-07-12 | 2006-01-18 | Ipsen Ltd | Botulinum neurotoxin composition |
| CN102139099A (zh) * | 2004-07-26 | 2011-08-03 | 莫茨药物股份两合公司 | 包含肉毒杆菌神经毒素的治疗组合物 |
| US20070196364A1 (en) * | 2004-07-27 | 2007-08-23 | Human Genome Sciences, Inc. | Pharmaceutical Formulation and Process |
| EP1776137B1 (en) | 2004-08-04 | 2014-11-26 | Ipsen Biopharm Limited | Pharmaceutical composition containing botulinum neurotoxin a2 |
| ES2526913T3 (es) | 2004-08-04 | 2015-01-16 | Ipsen Biopharm Limited | Composición farmacéutica que contiene neurotoxina 2 botulínica |
| GB2419526A (en) | 2004-10-28 | 2006-05-03 | Ipsen Ltd | Pharmaceutical composition containing botulinum neurotoxin |
| US7727537B2 (en) * | 2005-02-14 | 2010-06-01 | Dpm Therapeutics Corp. | Stabilized compositions for topical administration and methods of making same |
| US7838011B2 (en) * | 2005-02-14 | 2010-11-23 | Pankaj Modi | Stabilized protein compositions for topical administration and methods of making same |
| US9314431B2 (en) * | 2005-02-14 | 2016-04-19 | Transdermal Corp | Solubilized benzoyl small molecule |
| US9180081B2 (en) * | 2005-03-03 | 2015-11-10 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
| US8323666B2 (en) * | 2005-08-01 | 2012-12-04 | Allergan, Inc. | Botulinum toxin compositions |
| US8168206B1 (en) | 2005-10-06 | 2012-05-01 | Allergan, Inc. | Animal protein-free pharmaceutical compositions |
| US8137677B2 (en) * | 2005-10-06 | 2012-03-20 | Allergan, Inc. | Non-protein stabilized clostridial toxin pharmaceutical compositions |
| CN103126971A (zh) * | 2005-11-17 | 2013-06-05 | 雷文斯治疗公司 | 减少非毒素蛋白质的肉毒杆菌毒素组合物和其局部施用及透皮递送方法 |
| US9486408B2 (en) * | 2005-12-01 | 2016-11-08 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
| US7899450B2 (en) * | 2006-03-01 | 2011-03-01 | Telecommunication Systems, Inc. | Cellular augmented radar/laser detection using local mobile network within cellular network |
| US20090123527A1 (en) * | 2006-07-24 | 2009-05-14 | Akorn, Inc. | Method of inducing topical anesthesia and transdermal patch |
| WO2008079464A2 (en) * | 2006-09-08 | 2008-07-03 | Becton, Dickinson And Company | Stable powder formulations of alum-adsorbed vaccines |
| CN101848702B (zh) * | 2006-12-01 | 2013-07-17 | 安特里奥公司 | 两亲实体纳米粒子 |
| AU2007234612B2 (en) * | 2006-12-14 | 2013-06-27 | Johnson & Johnson Regenerative Therapeutics, Llc | Protein stabilization formulations |
| FR2910327B1 (fr) * | 2006-12-22 | 2013-04-26 | Scras | Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida. |
| CN102988995A (zh) * | 2006-12-29 | 2013-03-27 | 雷文斯治疗公司 | 用源自hiv-tat的多肽片段稳定的肉毒杆菌毒素的组合物及其局部施用和透皮递送的方法 |
| GB0700523D0 (en) * | 2007-01-11 | 2007-02-21 | Insense Ltd | The Stabilisation Of Proteins |
| MX2009012990A (es) | 2007-06-01 | 2010-04-01 | Merz Pharma Gmbh & Co Kgaa | Proceso para proporcionar un relajante muscular estable a la temperatura sobre la base del componente neurotoxico de toxina botulinica. |
| WO2009008595A1 (en) * | 2007-07-10 | 2009-01-15 | Medy-Tox, Inc. | Pharmaceutical liquid composition of botulinum toxin with improved stability |
| ES2805225T3 (es) * | 2007-07-26 | 2021-02-11 | Revance Therapeutics Inc | Péptidos antimicrobianos y composiciones de los mismos |
| WO2009056651A1 (en) * | 2007-11-02 | 2009-05-07 | Cytos Biotechnology Ag | Angiotensin-carrier formulation |
| US9107815B2 (en) * | 2008-02-22 | 2015-08-18 | Allergan, Inc. | Sustained release poloxamer containing pharmaceutical compositions |
| CN102307571A (zh) | 2008-12-10 | 2012-01-04 | 阿勒根公司 | 梭菌毒素药物组合物 |
| KR102179926B1 (ko) * | 2008-12-31 | 2020-11-17 | 레반스 테라퓨틱스, 아이엔씨. | 주사용 보툴리눔 독소 제제 |
| EP2248518B1 (en) * | 2009-04-17 | 2013-01-16 | Merz Pharma GmbH & Co. KGaA | Formulation for stabilizing proteins, peptides or mixtures thereof. |
| MX366344B (es) * | 2009-06-25 | 2019-07-05 | Revance Therapeutics Inc | Formulaciones de toxina botulinica libres de albumina. |
| CA2767392C (en) * | 2009-07-06 | 2017-03-14 | Variation Biotechnologies, Inc. | Methods for preparing vesicles and formulations produced therefrom |
| EP2473191B1 (en) * | 2009-09-04 | 2017-08-23 | XOMA Technology Ltd. | Antibody coformulations |
| LT2490986T (lt) * | 2009-10-21 | 2018-11-26 | Revance Therapeutics, Inc. | Nekompleksinio botulino neurotoksino gryninimo būdai ir sistemos |
| EP2493546A4 (en) * | 2009-10-30 | 2014-08-13 | Revance Therapeutics Inc | DEVICE AND METHOD FOR TOPICAL APPLICATION OF THERAPEUTIC OR COSMETIC COMPOSITIONS |
| CN102596145B (zh) * | 2009-10-30 | 2016-08-24 | 杜杰克特医疗系统有限公司 | 瓶间转移系统 |
| ES2639617T3 (es) * | 2010-10-12 | 2017-10-27 | Merz Pharma Gmbh & Co. Kgaa | Formulación adecuada para estabilizar proteínas, que carece de excipientes de mamíferos |
| DK2661276T3 (en) * | 2011-01-07 | 2017-10-02 | Revance Therapeutics Inc | TOPICAL COMPOSITION INCLUDING BOTULINUM TOXIN AND A COLOR |
| MX355771B (es) * | 2011-03-31 | 2018-04-30 | Medy Tox Inc | Preparacion liofilizada de toxinas de botulismo. |
| WO2013130535A1 (en) * | 2012-02-27 | 2013-09-06 | Newgen Biopharma Corporation | Topical delivery of hormonal and non hormonal nano formulations, methods of making and using the same |
| CA2889833A1 (en) * | 2012-10-28 | 2014-05-01 | Revance Therapeutics, Inc. | Compositions and methods for safe treatment of rhinitis |
| GB201407525D0 (en) * | 2014-04-29 | 2014-06-11 | Syntaxin Ltd | Manufacture of recombinant clostridium botulinum neurotoxins |
| MX380066B (es) | 2014-12-23 | 2025-03-11 | Merz Pharma Gmbh & Co Kgaa | Recipiente precargado con toxina botulinica. |
| SG10202004337WA (en) * | 2015-10-29 | 2020-06-29 | Revance Therapeutics Inc | Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect |
| FI126979B (en) * | 2016-02-29 | 2017-09-15 | Faron Pharmaceuticals Oy | Lyophilized pharmaceutical formulation and its use |
| MX2018012486A (es) * | 2016-04-12 | 2019-06-06 | Illustris Pharmaceuticals Inc | Composiciones para aplicacion topica de compuestos. |
| GEP20207139B (en) | 2016-05-27 | 2020-07-27 | Biopharm Limited Ipsen | Liquid neurotoxin formulation stabilized with tryptophan or tyrosine |
| WO2019046311A1 (en) * | 2017-08-28 | 2019-03-07 | Revance Therapeutics, Inc. | TRANSMUCOSAL COMPOSITIONS OF BOTULINUM TOXIN, KITS AND METHODS FOR TREATING BLADDER DISORDERS |
| US20200390871A1 (en) * | 2017-11-03 | 2020-12-17 | Revance Therapeutics, Inc. | Botulinum toxin formulations and methods of use thereof in plantar fascitis with extended duration of effect |
| CA3084175A1 (en) * | 2017-12-04 | 2019-06-13 | Revance Therapeutics, Inc. | Injectable botulinum toxin formulations and methods of use thereof having high response rate and long effect duration |
-
2010
- 2010-06-25 MX MX2016002034A patent/MX366344B/es unknown
- 2010-06-25 MX MX2012000174A patent/MX344583B/es active IP Right Grant
- 2010-06-25 CN CN201080035225.0A patent/CN102869373B/zh active Active
- 2010-06-25 US US13/380,131 patent/US20120107361A1/en not_active Abandoned
- 2010-06-25 JP JP2012517802A patent/JP6043627B2/ja not_active Expired - Fee Related
- 2010-06-25 WO PCT/US2010/040104 patent/WO2010151840A2/en not_active Ceased
- 2010-06-25 AU AU2010265888A patent/AU2010265888A1/en not_active Abandoned
- 2010-06-25 KR KR1020207035805A patent/KR102328155B1/ko active Active
- 2010-06-25 US US12/824,118 patent/US9340587B2/en active Active
- 2010-06-25 IL IL268980A patent/IL268980B/en unknown
- 2010-06-25 KR KR1020217037163A patent/KR20210141783A/ko not_active Withdrawn
- 2010-06-25 EP EP10792770.9A patent/EP2445521A4/en active Pending
- 2010-06-25 KR KR1020177034374A patent/KR101975051B1/ko active Active
- 2010-06-25 BR BRPI1015938A patent/BRPI1015938A2/pt not_active IP Right Cessation
- 2010-06-25 KR KR1020127001439A patent/KR101804279B1/ko active Active
- 2010-06-25 KR KR1020197012292A patent/KR102192618B1/ko active Active
- 2010-06-25 CA CA2766521A patent/CA2766521C/en active Active
- 2010-06-25 SG SG2011096153A patent/SG177357A1/en unknown
-
2011
- 2011-12-22 IL IL217156A patent/IL217156A0/en unknown
-
2012
- 2012-01-02 MX MX2019008126A patent/MX2019008126A/es unknown
- 2012-01-25 CO CO12010852A patent/CO6491076A2/es not_active Application Discontinuation
-
2016
- 2016-05-16 US US15/155,341 patent/US10111939B2/en active Active
-
2018
- 2018-10-30 US US16/175,434 patent/US11351232B2/en active Active
-
2021
- 2021-05-18 US US17/322,901 patent/US11911449B2/en active Active
-
2024
- 2024-01-16 US US18/414,311 patent/US20240382571A1/en active Pending